Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS StudyJokinen H.a, b · Kalska H.a · Ylikoski R.b · Madureira S.c · Verdelho A.c · van der Flier W.M.d · Scheltens P.d · Barkhof F.d · Visser M.C.d · Fazekas F.e · Schmidt R.e · O’Brien J.f · Waldemar G.g · Wallin A.h · Chabriat H.i · Pantoni L.j · Inzitari D.j · Erkinjuntti T.b
aDepartment of Psychology and the bMemory Research Unit, Department of Neurology, University of Helsinki, Helsinki, Finland; cServiço de Neurologia, Centro de Estudos Egas Moniz, Hospital de Santa Maria, Lisbon, Portugal; dDepartment of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; eDepartment of Neurology and MRI Institute, Medical University Graz, Graz, Austria; fInstitute for Ageing and Health, University of Newcastle, Newcastle-upon-Tyne, UK; gMemory Disorders Research Group, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark; hInstitute of Clinical Neuroscience, Goteborg University, Gothenburg, Sweden; iDepartment of Neurology, Hôpital Lariboisière, Paris, France; jDepartment of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Cross-sectional studies have indicated that subcortical ischemic vascular disease (SIVD), as defined according to imaging criteria, is associated with a specific clinical and cognitive profile. Much less is known about the long-term cognitive consequences of SIVD. The aim of the study was to investigate the longitudinal cognitive performance and incident dementia in subjects with and without SIVD in a sample of older adults with white matter lesions. Methods: In the Leukoaraiosis and Disability (LADIS) study, 639 participants were examined with annual clinical and neuropsychological evaluations for 3 years. The subjects meeting the MRI criteria of SIVD at baseline were compared to the other subjects of the sample with linear mixed models. Results: The overall level of cognitive performance over the follow-up period was inferior in multiple cognitive domains in SIVD subjects as compared to the reference group. The subjects with SIVD presented significantly steeper decline of performance in the Stroop test (parts I and II), Trail Making A test, Verbal fluency test, and Mini-Mental State Examination. They also had a threefold risk of developing dementia during follow-up independently of age, sex, education and medial temporal lobe atrophy. Conclusions: SIVD, as a manifestation of cerebral small vessel disease, is related to progressive cognitive impairment and a considerable risk of developing dementia. SIVD seems to specifically contribute to the deterioration of psychomotor speed, executive control, and global cognitive function.
© 2009 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.